”Androgens, especially dehydroepiandrosterone (DHEA), can be used concomitantly with ovulation promotion in patients with low ovarian reserve”, but the limited amount of data alone does not provide a basis for evidence-based treatment. Dehydroepiandrosterone has recently been used in women with low response to gonadotropins and in older women seeking assisted reproductive treatment. Although seemingly biologically plausible, recent evidence is still insufficient to prove its effectiveness. DHEA is secreted by the adrenal glands and is now widely used to improve ovarian response in those with low ovarian response. It is especially used during superovulation to increase the number of eggs retrieved. However, some recent studies have questioned its effectiveness. Therefore, we summarize the evidence regarding DHEA supplementation and discuss whether DHEA supplementation has an evidence-based treatment rationale. DHEA is an endogenous adrenal steroid hormone currently marketed as an over-the-counter drug and is widely used as a nutraceutical for anti-aging and enhancing sexual function. DHEA products available on the market are extracted from yam and can vary in purity and potency from 0-150% of the labeled amount. It is undeniably difficult to conduct randomized controlled trials in patients, especially in ovarian hyporesponders. However, neither the difficulty in obtaining Level I evidence nor the absence of harm justifies the recommendation of OTC drugs. While the merits reported in the literature are worth considering, they are still a long way from being “convincing”. Until a well-designed study with a large sample can confirm that DHEA improves ovarian response or reserve, the use of DHEA is best considered experimental only.